Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.23.

EBIT: As of FY2026 Q1, the actual value is USD -932 K.

Abpro Holdings, Inc. operates as a single reportable segment focused on the development of novel antibodies for immuno-oncology, ophthalmology, and infectious disease .

Financial Performance (Three Months Ended March 31, 2026 vs. 2025)

• Net Loss: The company reported a net loss of - $1,028 thousand for the three months ended March 31, 2026, which is an improvement compared to a net loss of - $3,887 thousand for the same period in 2025, representing a -74% change .

Operating Expenses

• Research and Development (R&D): R&D expenses decreased by - $312 thousand, or -96%, to $13 thousand in 2026 from $325 thousand in 2025, primarily due to a decrease in activities as R&D personnel were furloughed and terminated .
• General and Administrative (G&A): G&A expenses decreased by - $1,713 thousand, or -65%, to $920 thousand in 2026 from $2,633 thousand in 2025, driven by reductions in legal and accounting, facilities, litigation liability, and share-based compensation .
• Total Operating Expenses: Total operating expenses decreased by - $2,025 thousand, or -68%, to $933 thousand in 2026 from $2,958 thousand in 2025 .

Other Expense, Net

• Other expense, net, improved by $834 thousand, or -90%, to - $95 thousand in 2026 from - $929 thousand in 2025, mainly due to a non-recurring interest expense in Q1 2025 .

Cash Flow (Three Months Ended March 31, 2026 vs. 2025)

• Net Cash Used in Operating Activities: Net cash used in operating activities increased by - $577 thousand to - $2,080 thousand in 2026 from - $1,503 thousand in 2025, attributed to the timing of disbursements, including increased prepaids and decreased accounts payable .
• Net Cash Provided by (Used in) Financing Activities: Net cash provided by financing activities significantly increased by $7,495 thousand to $7,411 thousand in 2026, compared to - $84 thousand used in 2025, largely due to approximately $7.3 million from the sale of common stock shares under a Standby Equity Purchase Agreement (SEPA) .

Strategic Summary and Outlook

• Core Business Focus: Abpro Holdings, Inc. is focused on developing next-generation antibody therapeutics using its proprietary DiversImmune® and MultiMabTM platforms, with key product candidates ABP-102 and ABP-201 slated for preclinical activities and clinical trials, including planned Phase ¹⁄₂ and Phase 1 trials respectively .
• Funding and Going Concern: As of March 31, 2026, the company had $5,398 thousand in cash, but management concluded there is substantial doubt about its ability to continue as a going concern, anticipating continued operating losses and negative cash flows . The company plans to seek additional funding through equity and debt financings, collaboration agreements, and research grants, acknowledging that a lack of adequate funds could lead to delays or elimination of R&D programs .
• Nasdaq Delisting: The company’s common stock was delisted from Nasdaq on February 23, 2026, and now trades on the OTCQB, Pink Limited tier, with an appeal against the delisting determination filed on March 18, 2026, expecting a response in June 2026 .